<DOC>
	<DOC>NCT01159769</DOC>
	<brief_summary>The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.</brief_summary>
	<brief_title>Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>12 years of age or older. History (within the past 24 months) of allergic conjunctivitis. Active signs and symptoms of ocular allergies. Ocular health within normal limits, as determined by the investigator or subinvestigator. Willing to avoid contact lens wear each study visit immediately prior to study medication instillation and for 10 minutes after instillation of study drug. Other protocoldefined inclusion criteria may apply. Contraindications or hypersensitivity to study medication or its components. One sighted eye or not correctable to 0.6 logMAR or better in both eyes at the screening visit. Known history of recurrent corneal erosion syndrome. Ocular trauma or surgical intervention within 6 months prior to Visit 1. Participation in any other investigational study within 30 days before Visit 1. Pregnant or nursing. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Allergic conjunctivitis</keyword>
</DOC>